Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug boost brain recovery after stroke?

NCT ID NCT07511543

Disease control Sponsor: Population Health Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 4 times

Summary

This pilot study tests whether giving semaglutide (Ozempic) to 100 stroke patients who had a clot-removal procedure can improve recovery. Patients are randomly assigned to receive weekly injections for 12 weeks or no drug. The main goal is to see if a larger, definitive trial is possible by tracking recruitment, adherence, and retention. If successful, it could lead to a bigger study aiming to reduce death and long-term disability after stroke.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (Ozempic), a weekly injection under the skin
What this could lead to
If this pilot shows it's feasible, it could pave the way for a larger study testing whether semaglutide reduces death and disability after a severe stroke.
What could go wrong
This is a very early, small pilot study (100 people) focused on feasibility, not on proving the drug works. Even if feasible, semaglutide may not improve stroke recovery and could have side effects like nausea or low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or above on the date of randomization. 2. EVT for an LVO in the anterior circulation, defined as the intracranial segment of the internal carotid artery (ICA) and/or the M1 or proximal M2 segment of the middle cerebral artery (MCA). 3. National Institutes of Health Stroke Scale (NIHSS) ≥ 6 points at the time of randomization. 4. Pre-stroke modified Rankin Scale (mRS) 0 or 1. 5. Ability to randomize within 6 hours from the end of EVT. 6. Capable of giving signed informed consent either independently, or by a legally authorized representative (LAR). Exclusion Criteria: 1. Pregnancy or breast-feeding. 2. Renal insufficiency (creatinine clearance \< 30mL/min). 3. Cirrhosis or severe hepatic dysfunction, characterized by jaundice, encephalopathy or coagulopathy. 4. History of pancreatitis in the year prior to randomization or evidence of acute pancreatitis on randomization. 5. Active sepsis on randomization. 6. Cancer, regionally advanced or metastatic, or for which treatment had been administered within 6 months from randomization, or hematological cancer that is not in complete remission. 7. Any terminal medical condition with life expectancy of less than 3 months. 8. Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). 9. Body mass index (BMI) less than 19. 10. Known hypersensitivity to GLP-1 RAs. 11. Active treatment with an GLP-1RA prior to randomization. 12. Refusal or inability to administer subcutaneous (SC) injections by the patient or a caregiver. 13. Close affiliation with the investigational site.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke due to anterior circulation large vessel occlusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral artery occlusion ischemic stroke large artery stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.